4 January 2017 - Approximately 15,000 people in Germany develop renal cell carcinoma every year.

The German IQWiG has published a report which concludes that an additional benefit for Kisplyx (lenvatinib mesylate) in combination with everolimus for the treatment of advanced renal cell carcinoma versus the established comparator therapy - as defined by the Federal Joint Committee (G-BA), has been proven.

The final decision to implement the report's recommendation lies with the G-BA and is expected for March 2017. It will follow consideration of the IQWiG report, written statements and an oral hearing.

Eisai´s request for an accelerated assessment was agreed upon by the CHMP on 19 November 2015 as the product was considered to be of major public health interest. In August 2016, the European Commission issued the marketing authorisation for lenvatinib in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor-targeted therapy.

Read Eisai press release